

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

UNITED STATES DISTRICT COURT  
WESTERN DISTRICT OF WASHINGTON  
AT SEATTLE

SEAGEN INC.,

Petitioner,

v.

DAIICHI SANKYO CO., LTD.,

Respondent.

CASE NO. C22-1613JLR

ORDER

**I. INTRODUCTION**

Before the court are (1) Petitioner Seagen Inc.’s (“Seagen”) petition to vacate an August 11, 2022 interim arbitration award and a November 17, 2023 final arbitration award (together, the “Award”) (Petition (Dkt. # 78); Pet. Mem. (Dkt. ## 81 (sealed), 115 (redacted)); Pet. Reply (Dkt. ## 116 (sealed), 118 (redacted)); *see* 12/1/23 Chivvis Decl. (Dkt. # 82) ¶ 2, Ex. 77 (“Award”); 12/13/23 Chivvis Decl. (Dkt. # 89) ¶ 5, Ex. 4

//

//

1 (“Interim Award”))<sup>1</sup>; and (2) Respondent Daiichi Sankyo Co., Ltd.’s (“DSC”)   
2 cross-motion to confirm the Award (Resp. Mem. (Dkt. # 112); Resp. Reply (Dkt. # 120)).   
3 The court has considered the parties’ submissions, the relevant portions of the record, and   
4 the governing law. Being fully advised,<sup>2</sup> the court DENIES Seagen’s petition to vacate   
5 the Award and GRANTS DSC’s cross-motion to confirm the Award.

## 6 II. BACKGROUND

7 This case arises out of a failed partnership between Seagen, a Bothell-based   
8 biotech company, and DSC, a Japanese pharmaceutical company. (*See generally*   
9 12/13/23 Chivvis Decl. ¶ 2, Ex. 1 (Dkt. ## 89-1 (cover page), 90 (sealed))   
10 (“Collaboration Agreement”).) Seagen describes itself as a “pioneer” in antibody-drug   
11 conjugates (“ADCs”) and holds several patents relating to the technology. (Pet. Mem. at   
12 3; *see* Collaboration Agreement at 39-40<sup>3</sup> (listing Seagen patents).) According to   
13 Seagen, DSC was interested in its ADC technology and initiated negotiations that   
14 eventually led to the execution of a collaboration agreement on July 2, 2008. (*See* Pet.   
15 Mem. at 4. *See generally* Collaboration Agreement.) That agreement granted DSC a   
16 license to develop, manufacture, and sell Seagen’s proprietary ADC technology. (*See*   
17 *generally* Collaboration Agreement.) The collaboration agreement, however, didn’t work

18 

---

  
19 <sup>1</sup> Because the final arbitration award “fully adopts and integrates by reference” the   
interim award (except where otherwise specified), all references and citations to the “Award” in   
this order refer to the final arbitration award. (Award at 20.)


20 <sup>2</sup> Neither party requests oral argument (*see* Petition at 1; Pet. Mem. at 1; Resp. at 1), and   
21 the court concludes that oral argument would not be helpful to its disposition of Seagen’s   
petition or DSC’s cross-motion, *see* Local Rules W.D. Wash. LCR 7(b)(4).

22 <sup>3</sup> Citations to the collaboration agreement reference page numbers in the CM/ECF   
header.

1 out, and DSC terminated the agreement in 2015. (Award at 9.) Years later, on  
2 November 12, 2019, Seagen filed a demand for arbitration for breach of contract and  
3 quiet title claims against DSC, arguing that DSC improperly filed patent applications on  
4 Seagen’s technology and incorporated that technology into its own drug pipeline.  
5 (12/13/23 Chivvis Decl. ¶ 3, Ex. 2 (arbitration demand) at 1-2.) The case proceeded to  
6 arbitration, and on November 14, 2023, the Arbitrator issued a 67-page final arbitration  
7 award in DSC’s favor. (*See generally* Award.) Below, the court summarizes the relevant  
8 technology, the parties’ collaboration agreement, and the Arbitrator’s conclusions and  
9 reasoning.

#### 10 1. ADC Technology

11 ADCs are a family of therapeutic agents that can be used to treat various cancers.  
12 (*See* 12/13/23 Chivvis Decl. ¶ 7, Ex. 6 (Dkt. ## 89-6 (cover page), 91-1 (sealed)) (“3/5/21  
13 Bertozzi Rpt.”) ¶¶ 25-27.) They comprise a Y-shaped monoclonal antibody, a cytotoxic  
14 drug called the “payload,” and a “linker” component connecting the payload to the  
15 antibody. (*Id.* ¶¶ 23, 25-26.) The following image is a representation of an ADC:



1 (*Id.* ¶ 26.) The antibodies used in ADCs “preferentially target cancer cells over normal  
2 cells due to the presence of antigens on the surface of the cancer cells.” (*Id.* ¶ 27.) This  
3 provides a significant advantage over traditional chemotherapy, in which “drugs are  
4 administered in an untargeted fashion,” harming both cancer cells and normal, healthy  
5 cells. (*Id.*) The toxic payload in an ADC “gets delivered where it is needed,” meaning  
6 ADCs function like “smart bombs that target cancer cells.” (*Id.*)

7 Various antibodies, payloads, and linkers can be used in ADCs. (*See id.*  
8 ¶¶ 28-29.) Different antibodies seek out different cancer cells, meaning the antibody  
9 used in a treatment for one type of cancer may not be effective against another. (*See id.*  
10 Annex B at 4.) There are also several families of payload drugs, which kill cancer cells  
11 in different ways. Two such examples are camptothecin and auristatin derivatives, which  
12 inhibit different enzymes and proteins necessary for cells to live and reproduce. (*See id.*  
13 Annex B at 4-5; Award at 42.) Linking the chosen antibody to the desired payload  
14 presents “one of the most complex problems that researchers have faced in developing  
15 ADCs” because the bond must be strong enough to remain stable in the blood stream and  
16 yet permit release of the payload drug once the ADC arrives at a cancer cell. (3/5/21  
17 Bertozzi Rpt. ¶ 28.) Some linkers are so strong that the entire antibody must dissolve in a  
18 cancer cell before the payload is released, but other linkers quickly degrade when  
19 exposed to certain environments or enzymes inside a cancer cell, providing for a more  
20 efficient release. (*See id.* ¶¶ 29-37 (describing acid-cleavable and protease-cleavable  
21 linkers).)

22 //

1 Altogether, the right antibody, payload, and linker combine to form an inspiring  
2 cancer treatment.

3 2. The Collaboration Agreement

4 The parties' July 2, 2008 collaboration agreement contemplates ownership rights  
5 of "Improvements" related to the "Drug Conjugation Technology" at issue. (*E.g.*,  
6 Collaboration Agreement at 12.) Section 3.3.1 describes the parties' rights to any such  
7 improvements:

8 3.3.1 **Improvements**. In the event that, during the Term, [DSC] conceives,  
9 develops or reduces to practice an Improvement that relates to the Drug  
10 Conjugation Technology, [DSC] shall promptly notify [Seagen] of the  
11 discovery of such Improvement. [Seagen] shall own all such Improvements  
12 that relate to the Drug Conjugation Technology and, to the extent that such  
13 Improvements shall have been conceived, developed or reduced to practice  
14 by [DSC], [DSC] hereby assigns all of its right, title and interest therein to  
15 [Seagen]. [Seagen's] interest in any such Improvements that it Controls shall  
16 be included in the [Seagen] Technology and made available to [DSC] via the  
17 Exclusive License provided in Article 3. [DSC] may use such Improvement  
18 assigned to [Seagen] by [DSC] for any purpose within the scope of the  
19 Exclusive License granted herein solely during the Term of this Agreement.

20 (*Id.* at 12.) The collaboration agreement defines the terms "Improvements" and "Drug  
21 Conjugation Technology" at sections 1.1.32 and 1.1.17, respectively:  
22

1.1.32 **"Improvements"** means all patentable or non-patentable inventions,  
discoveries or other know-how developed and Controlled by either Party  
after the Effective Date that utilize, incorporate, derive directly from, directly  
relate to, are made using or are based directly on the [Seagen] Technology  
.....

1.1.17 **"Drug Conjugation Technology"** means (a) cytotoxins or cytostatic  
compounds such as monomethyl Auristatin E and monomethyl Auristatin F  
and certain variants, derivatives, analogues and salts thereof, and methods of  
making and using such cytotoxic or cytostatic compounds (b) compositions  
and methods useful for attaching the foregoing cytotoxic or cytostatic

1 compounds to antibodies and (c) any related assays and methods [Seagen]  
2 provides to Licensee pursuant to the Research Program.

3 (*Id.* at 4-5.) The collaboration agreement also contains a provision concerning attorneys'  
4 fees and costs:

5 19.3.4 . . . The judgment rendered by the arbitrator shall include costs of  
6 arbitration, reasonable attorneys' fees and reasonable costs for expert and  
7 other witnesses.

8 (*Id.* at 33.) Washington law governs the collaboration agreement. (*Id.*)

9 3. The Award

10 During arbitration, Seagen argued that DSC breached the collaboration agreement  
11 by “naming itself as owner of the Improvement IP” and sought to quiet title “to confirm  
12 Seagen’s ownership of the Improvement IP.” (Petition ¶ 20.) The Arbitrator rejected  
13 Seagen’s claims, concluding that both “fail[ed] for essentially straightforward reasons.”  
14 (Award at 22.) The Arbitrator then awarded DSC attorneys’ fees and costs. (*Id.* at 66.)

15 a. *Breach of Contract*

16 With respect to Seagen’s breach of contract claim, the Arbitrator concluded that  
17 the claim was time-barred because the statute of limitations had expired. (*See id.* at 30.)  
18 The Arbitrator found that the claim accrued—at the latest—on October 11, 2012, the date  
19 DSC filed a patent application in its own name constructively reducing its ADC  
20 technology to practice. (*Id.* at 27.) Noting that Washington has a six-year statute of  
21 limitations for breach of contract actions, the Arbitrator concluded that Seagen’s  
22 November 12, 2019 arbitration demand came 13 months too late. (*Id.* at 30.) Seagen

//

1 does not challenge the Arbitrator’s decision on its breach of contract claim. (Pet. Mem.  
2 at 1 n.2.)

3 *b. Quiet Title*

4 The Arbitrator rejected Seagen’s claim for quiet title on two distinct grounds:  
5 (1) like the breach of contract claim, the claim for quiet title was time-barred; and  
6 (2) DSC’s alleged “Improvement IP” did not meet the definition of “Drug Conjugation  
7 Technology” under Section 1.1.17 of the collaboration agreement. (Award at 39-40, 45.)

8 First, with respect to the time bar, the Arbitrator acknowledged that Washington  
9 generally does not have a statute of limitations for quiet title actions. (*Id.* at 37.) But the  
10 Arbitrator also acknowledged that, in Washington, “[t]he gravamen of the claim  
11 determines the applicable statute of limitations.” (*Id.* (quoting *Aberdeen Fed. Sav. &*  
12 *Loan Ass’n v. Hanson*, 794 P.2d 1322, 1324 (Wash. Ct. App. 1990)).) The Arbitrator  
13 concluded that the “gravamen” of Seagen’s quiet title claim was “quintessentially  
14 contractual” and therefore time barred because the claim (1) “solely ar[ose] from Section  
15 3.3.1 of the Collaboration Agreement,” (2) could not “plausibly be determined without  
16 undertaking the same breach of contract analysis mandated by Seagen’s Breach of  
17 Contract Claim,” and (3) was ultimately “nothing more than a request for specific  
18 performance of Section 3.3.1.” (*Id.* at 37-38.) The Arbitrator recognized that, “while  
19 Seagen decline[d] to identify Section 3.3.1 in conjunction with its Quiet Title Claim, it  
20 specifically quote[d]—though without attribution—two clauses from Section 3.3.1 as the  
21 express and sole basis for that claim.” (*Id.* at 38.) Accordingly, the Arbitrator concluded

22 //

1 that the applicable statute of limitations for breach of contract applied to and barred  
2 Seagen’s quiet title claim as a matter of Washington law. (*Id.*)

3         Second, the Arbitrator concluded in the alternative that DSC’s alleged  
4 “Improvement IP” did not, under the terms of the collaboration agreement, constitute an  
5 “Improvement” related to “Drug Conjugation Technology” because DSC’s alleged  
6 improvement utilized a different payload drug than that expressly contemplated in the  
7 agreement. (*See id.* at 39-46.) The Arbitrator reasoned that, because section 1.1.17  
8 defined “Drug Conjugation Technology” in part as “cytotoxins or cytostatic compounds  
9 *such as* monomethyl *Auristatin* E and monomethyl *Auristatin* F and certain variants,  
10 derivatives, analogues and salts thereof,” Seagen’s claim failed for a simple reason:  
11 DSC’s “improvement” utilized a “proprietary *camptothecin*” payload “that it had already  
12 developed at the time the Collaboration Agreement was executed.” (*Id.* at 41 (quoting  
13 Collaboration Agreement at 4 (emphasis added)), 44 (emphasis added).) The Arbitrator  
14 rejected Seagen’s argument that the “such as” language in section 1.1.17 was nonlimiting  
15 for three reasons: (1) such an interpretation was inconsistent with Washington’s  
16 “objective manifestation” theory of contract interpretation; (2) Seagen’s interpretation  
17 would render the clause “substantively meaningless, and therefore superfluous”; and  
18 (3) it was inconsistent with a “more objectively reasonable interpretation . . . that the  
19 Parties commonsensically intended to tether the scope of the term ‘Drug Conjugation  
20 Technology’ to the type of ADC technology that Seagen actually possessed,” which  
21 utilized auristatin payloads. (*Id.* at 43-44.)

22 //



1           c.       *Attorneys' Fees and Costs*

2           Having ruled in favor of DSC, the Arbitrator assessed fees in accordance with  
3 section 19.3.4. (*See id.* at 46-66.) The Arbitrator considered DSC's request for a total  
4 award of \$58,092,301.58 and ¥3,436,666.00 and Seagen's objections thereto. (*See id.* at  
5 47.) DSC's requested award consisted of (1) the Arbitrator's fees and expenses;  
6 (2) hearing and support services expenses; (3) outside counsel attorneys' fees and  
7 expenses; (4) expert witness fees and expenses; and (5) fact witness expenses. (*Id.* at 47.)

8           The Arbitrator recognized DSC's burden under Washington law to prove that its  
9 requested fees and costs were "reasonable" and that, to meet that burden, DSC was  
10 required to provide documentation of the work performed in order to allow the Arbitrator  
11 to assess whether the number of hours expended was reasonable. (*Id.* at 48 (quoting  
12 *Zones, Inc. v. Evergreen Info. Tech Servs., Inc.*, No. C17-0457RAJ, 2019 WL 6894676,  
13 at \*1 (W.D. Wash. Dec. 18, 2019)).) The Arbitrator considered a 113-page categorical  
14 chart submitted by DSC that, for each month beginning in September 2019 through June  
15 2022, provided the following nine columns of information:

- 16           1. "Task Categories" explaining the work undertaken by DSC's Counsel;
- 17           2. "Timekeeper Category" explaining the role/position of the individuals billing;
- 18           3. "Effective Billed Rate," essentially providing an average hourly rate in U.S.  
19           Dollars;
- 20           4. "Billed Rate Range" explaining the range of hourly rates in U.S. Dollars for  
21           each "Timekeeper Category";
- 22           5. "Hours" – the total number of hours billed;

- 1 6. “Timekeeper Category Total” in U.S. Dollars;
- 2 7. “Monthly Task Category Total” in U.S. Dollars;
- 3 8. “Monthly Invoice Total” in U.S. Dollars; and
- 4 9. “Monthly Amount Requested” – the attorneys’ fees actually incurred by DSC  
5 in U.S. Dollars net of any discounts that were negotiated from the invoice  
6 amount.

7 (*Id.* at 53.) The Arbitrator then set forth and applied the two-step “lodestar” methodology  
8 Washington courts apply when determining reasonable attorneys’ fees. (*Id.* at 54 (citing  
9 *Berryman v. Metcalf*, 312 P.3d 745, 753 (Wash. Ct. App. 2013)).)

10 At step one of the lodestar methodology, where the “decision-maker determines a  
11 lodestar base by multiplying a reasonable hourly rate by the number of hours reasonably  
12 expended,” (*id.* at 54 (citing *Bowers v. Transam. Title Ins. Co.*, 675 P.2d 193, 201 (Wash.  
13 1983)), the Arbitrator was “clearly convinced that DSC ha[d] carried its burden of  
14 proving that its requested attorneys fees [were] ‘reasonable’” (*id.* at 54-55). The  
15 Arbitrator concluded that DSC’s 113-page chart “cogently organized the information  
16 necessary to support a lodestar base calculated both on a micro level (because [the chart]  
17 fundamentally provide[d] a discrete lodestar basis for each month in which DSC incurred  
18 attorneys’ fees), as well as on a macro level (because the monthly data aggregate[d] into  
19 DSC’s overall lodestar basis).” (*Id.* at 55.)

20 At step two of the lodestar methodology, where the burden shifts to the party  
21 opposing the fee award to establish that the decision-maker should “adjust the . . . base to  
22 reflect factors not yet considered, such as the contingent nature of success in the action or

1 the quality of the legal representation” (*id.* at 54 (citing *Bowers*, 675 P.2d at 201-04)), the  
2 Arbitrator concluded that Seagen “generally” did not carry its burden (*id.* at 54-56). The  
3 Arbitrator considered and rejected Seagen’s arguments in favor of large rate reductions.  
4 (*See id.* at 56-62.) The Arbitrator did, however, agree with Seagen that a 5% reduction to  
5 the fees charged by Paul Hastings LLP was appropriate “to match the blended hourly  
6 rates that Seagen was charged.” (*Id.* at 58.)

7 With respect to costs, Seagen did not challenge DSC’s request for arbitration  
8 costs, expert witness costs and fees, and fact witness costs. (*Id.* at 62.) Concerning  
9 DSC’s request for over \$10,000,000 in costs for various other “expenses,” the Arbitrator  
10 agreed with Seagen that such costs were “not allowable under Section 19.3.4 of the  
11 Collaboration Agreement.” (*Id.* at 64-65.) DSC does not challenge this ruling. (*See*  
12 *Resp. Mem.* at 21.)

13 Below, the court sets forth the relevant legal standard before turning to the merits  
14 of Seagen’s petition to vacate the Award and DSC’s cross-motion to confirm the Award.

### 15 III. LEGAL STANDARD

16 The Federal Arbitration Act (“FAA”) “states that if a party seeks a judicial order  
17 confirming an arbitration award, ‘the court must grant such an order unless the award is  
18 vacated, modified, or corrected as prescribed in sections 10 and 11 of this title.’”  
19 *Kyocera Corp. v. Prudential-Bache Trade Servs., Inc.*, 341 F.3d 987, 997 (9th Cir. 2003)  
20 (en banc) (quoting 9 U.S.C. § 9). “[C]onfirmation is required even in the face of  
21 erroneous findings of fact or misinterpretations of law.” *Id.* (quoting *French v. Merrill*  
22 *Lynch, Pierce, Fenner & Smith, Inc.*, 784 F.2d 902, 906 (9th Cir. 1986)). In relevant part,

1 Section 10 allows for vacatur only “where the arbitrators exceeded their powers.” 9  
2 U.S.C. § 10(a)(4).

3 “Arbitrators exceed their powers when they express a ‘manifest disregard of law,’  
4 or when they issue an award that is ‘completely irrational.’” *Bosack v. Soward*, 586 F.3d  
5 1096, 1104 (9th Cir. 2009) (quoting *Comedy Club, Inc. v. Improv W. Assocs.*, 553 F.3d  
6 1277, 1290 (9th Cir. 2009)). These grounds provide the district court with “extremely  
7 limited review authority,” *Kyocera*, 341 F.3d at 998, and the burden rests on the party  
8 seeking vacatur, *U.S. Life Ins. Co. v. Superior Nat’l Ins. Co.*, 591 F.3d 1167, 1173 (9th  
9 Cir. 2010).

10 “To demonstrate manifest disregard, the moving party must show that the  
11 arbitrator understood and correctly stated the law, but proceeded to disregard the same.”  
12 *Hayday Farms, Inc. v. FeeDx Holdings, Inc.*, 55 F.4th 1232, 1241 (9th Cir. 2022)  
13 (quoting *Bosack*, 586 F.3d at 1104). This standard “requires something beyond and  
14 different from a mere error in the law or failure on the part of the arbitrators to  
15 understand and apply the law.” *Id.* at 1240 (quoting *Bosack*, 586 F.3d at 1104). “There  
16 must be some evidence in the record, other than the result, that the arbitrators were aware  
17 of the law and intentionally disregarded it.” *Id.* at 1241 (quoting *Bosack*, 586 F.3d at  
18 1104). The court also “must accept the arbitrator’s findings of fact.” *Id.* (citing *Carter v.*  
19 *Health Net of Cal., Inc.*, 374 F.3d 830, 838 (9th Cir. 2004)).

20 Under the “completely irrational” standard, the moving party must establish that  
21 the award “ignores controlling terms of the parties’ contract.” *Id.* at 1241. The test is  
22 “whether the arbitrator’s decision draws its essence from the contract” rather than “the

1 rightness or wrongness of the arbitrator’s contract interpretation.” *Id.* at 1241 (quoting  
2 *Aspic Eng’g & Constr. Co. v. ECC Centcom Constructors LLC*, 913 F.3d 1162, 1166 (9th  
3 Cir. 2019)). The court will not disturb the arbitrator’s award so long as it sets forth “a  
4 plausible interpretation of the arbitration contract.” *Id.* (quoting *U.S. Life Ins. Co.*, 591  
5 F.3d at 1177). “Accordingly, the court must defer to the arbitrator’s decision as long as  
6 the arbitrator even arguably construed or applied the contract.” *Id.* (quoting *U.S. Life Ins.*  
7 *Co.*, 591 F.3d at 1177).

8 The “manifest disregard” and “completely irrational” standards are purposefully  
9 deferential and “designed to preserve due process but not to permit unnecessary public  
10 intrusion into private arbitration procedures.” *Kyocera*, 341 F.3d at 998. The  
11 “simplicity, informality, and expedition of arbitration” are “attributes not normally  
12 associated with federal trials,” and courts must take care not to “render[] informal  
13 arbitration merely a prelude to a more cumbersome and time-consuming judicial review  
14 process.” *Id.* (quoting *Mitsubishi Motors Corp. v. Soler Chrysler-Plymouth, Inc.*, 473  
15 U.S. 614, 628 (1985)). Sections 9 through 11 of the FAA therefore “substantiat[e] a  
16 national policy favoring arbitration with just the limited review needed to maintain  
17 arbitration’s essential virtue of resolving disputes straightaway.” *Hall St. Assocs., L.L.C.*  
18 *v. Mattel, Inc.*, 552 U.S. 576, 588 (2008).

#### 19 **IV. THE ARBITRATOR’S AWARD**

20 Seagen argues that the Arbitrator exceeded his powers. (See Petition ¶ 26.) In  
21 particular, Seagen takes issue with the Arbitrator’s (1) interpretation of “Drug  
22 Conjugation Technology” in the collaboration agreement; (2) statute of limitations ruling;

1 and (3) fee award to DSC. (*Id.* ¶¶ 26-29.) The court considers Seagen’s arguments  
2 below before turning to DSC’s requests for prejudgment and postjudgment interest and  
3 attorneys’ fees and costs.

4 **A. “Drug Conjugation Technology”**

5 Seagen argues that the Arbitrator exceeded his powers with respect to his  
6 interpretation of “Drug Conjugation Technology” in section 1.1.17 for two reasons:  
7 (1) the Arbitrator misconstrued the “such as” language in section 1.1.17 to be limiting;  
8 and (2) the Arbitrator failed to consider subparts (b) and (c) of section 1.1.17. (Pet. Mem.  
9 at 12-14.) Seagen posits that the Arbitrator “determined what is fair and then worked  
10 backwards to achieve that desired result in disregard of the plain text of the agreement.”  
11 (*Id.* at 15.) Seagen’s arguments are not well taken.

12 The question is not whether the Arbitrator correctly interpreted section 1.1.17, but  
13 whether he “even arguably construed or applied” it. *Hayday Farms*, 55 F.4th at 1241  
14 (quoting *U.S. Life Ins. Co.*, 591 F.3d at 1177). The Arbitrator undoubtedly did so. He  
15 began his analysis by quoting section 1.1.17 in its entirety. (Award at 40-41.) The  
16 Arbitrator then considered—and rejected—Seagen’s interpretation of the “such as”  
17 language in section 1.1.17 and concluded that “DSC’s proposed interpretation” of “Drug  
18 Conjugation Technology” was more “objectively reasonable” than Seagen’s. (*Id.* at  
19 42-45.) For the reasons stated below, the court will not disturb the Arbitrator’s  
20 conclusions.

21 First, the Arbitrator plausibly interprets “such as” as limiting “Drug Conjugation  
22 Technology” to ADCs containing auristatin-derived payloads. As the Arbitrator correctly

1 recognized, Washington follows the objective manifestation theory of contract  
2 interpretation, which focuses on the “reasonable meaning of the contract language to  
3 determine the parties’ intent.” (*Id.* at 43 (quoting *RSD AAP, LLC v. Alyeska Ocean, Inc.*,  
4 358 P.3d 483, 488 (Wash. Ct. App. 2015)).) Under this theory, “a contract can be  
5 informed not only by its language, but also by its subject matter and objective, all the  
6 circumstances surrounding its making, and the reasonableness of the respective  
7 interpretations advocated by the parties.” (*Id.* (quoting *Wash. Pro. Real Est., LLC v.*  
8 *Young*, 360 P.3d 59, 63 (Wash. Ct. App. 2015)).) The Arbitrator concluded that a  
9 limiting interpretation of “such as” best “effectuates the objective manifestation theory of  
10 contract interpretation” because Seagen’s ADC technology utilizes auristatin payloads  
11 and the only “cytotoxins or cytostatic compounds” mentioned in section 1.1.17 are  
12 auristatins. (*Id.* at 42-44.) The parties therefore “commonsensically intended to tether  
13 the scope of the term ‘Drug Conjugation Technology’ to the type of ADC technology that  
14 Seagen actually possessed.” (*Id.*) Seagen’s contrary interpretation, on the other hand,  
15 would have given it the right to improvements in “a proprietary cytotoxin that [DSC] had  
16 already developed at the time the Collaboration Agreement was executed.” (*Id.* at 44.)  
17 The Arbitrator’s reasoning is not just plausible but persuasive. The court therefore rejects  
18 Seagen’s argument that the Arbitrator “redefine[d] the term ‘such as’ to reach a preferred  
19 outcome.” (Pet. Mem. at 14.)

20         Second, the Arbitrator did not ignore subparts (b) and (c); he did not need to  
21 consider them. Again, the Arbitrator began his analysis by quoting section 1.1.17 in full,  
22 including subparts (b) and (c). (*See id.* at 40-41.) Seagen argues that it made a “powerful

1 showing” that its linker technology is “useful for attaching antibodies to many different  
2 kinds of payloads” (Pet. Mem. at 13-14), but it ignores the plain language of subpart (b),  
3 which is limited to “compositions and methods useful for attaching the *foregoing*  
4 cytotoxic or cytostatic compounds to antibodies” (Collaboration Agreement at 4  
5 (emphasis added)). The only “foregoing” cytotoxic compounds are the auristatins listed  
6 in subpart (a). (Collaboration Agreement at 4.) Seagen further argues that “[n]othing in  
7 subpart (c) is even arguably limited to ‘auristatins,’” but it is wrong. (Pet. Mem. at 13.)  
8 Subpart (c) discusses “*related* assays and methods,” meaning it is, “arguably,” limited to  
9 the auristatins mentioned in subpart (a). (Collaboration Agreement at 4 (emphasis  
10 added).) Seagen’s overconfidence on these points in its opening brief is unjustified and  
11 disappointing.

12 As it pertains to the definition of “Drug Conjugation Technology,” the Award is  
13 not completely irrational, nor does it exhibit a manifest disregard for the law. Because  
14 the Arbitrator neither disregarded the controlling law nor ignored the collaboration  
15 agreement’s controlling terms, the court AFFIRMS the Award on this ground.

## 16 **B. Statute of Limitations**

17 The court next considers the Arbitrator’s alternative conclusion that the statute of  
18 limitations bars Seagen’s claim for quiet title. Seagen argues that the Arbitrator exceeded  
19 his powers by (1) “acknowledg[ing] that Washington law has no statute of limitations for  
20 quiet title claims” and yet still applying one, and (2) ignoring the “hereby assigns” clause  
21 in section 3.3.1 of the collaboration agreement. (Pet. Mem. at 19-22.) The court does not  
22 agree.



1 To begin, Seagen fails to meet its burden to show that the Arbitrator disregarded  
2 the applicable law. Seagen must show more than “a mere error in the law”; it must  
3 establish that the Arbitrator “understood and correctly stated the law, but proceeded to  
4 disregard the same.” *Hayday Farms*, 55 F.4th at 1242 (quoting *Bosack*, 586 F.3d at  
5 1104). According to Seagen, the Arbitrator recognized that Washington has no statute of  
6 limitations for quiet title claims “but applied one anyway.” (Pet. Mem. at 2.) Seagen’s  
7 argument fails because the Arbitrator did not “disregard” the applicable law. Rather, he  
8 considered it head-on. As the Arbitrator recognized, it is the “gravamen” of the  
9 underlying cause of action that determines the applicable statute of limitations. (Award  
10 at 37 (quoting *Aberdeen*, 794 P.2d at 1324).) The Arbitrator concluded that the  
11 “gravamen” of Seagen’s quiet title claim was “a breach of Section 3.3.1 of the  
12 Collaboration Agreement.” (*Id.* at 38.) Seagen cites several cases in which courts have  
13 held that a breach of contract statute of limitations did not apply to a quiet title claim (Pet.  
14 Mem. at 20 (collecting cases)), but the court is not persuaded by this line of authority in  
15 light of the Arbitrator’s reasonable conclusion that the essence of Seagen’s claim was not  
16 quiet title but breach of contract. It is notable and illuminating that Seagen neither  
17 addresses nor attempts to explain the Arbitrator’s observation that Seagen “specifically  
18 quote[d]—though without attribution—two clauses from Section 3.3.1 as the express and  
19 sole basis for [its] claim.” (Award at 38. *See generally* Pet. Mem.)

20 Seagen pivots and argues that the Award is “irrational” because the Arbitrator  
21 “disregard[ed] the ‘hereby assigns’ language” in section 3.3.1. (Pet. Mem. at 21.) Again,  
22 the Arbitrator did no such thing. The Arbitrator explicitly addressed Seagen’s claim for

1 “quiet title to the Improvement IP via the ‘*hereby assigns*’ clause in Section 3.3.1” and  
2 concluded that Seagen’s claim could not “plausibly be determined without undertaking  
3 the same breach of contract analysis mandated by Seagen’s Breach of Contract Claim.”  
4 (Award at 38 (emphasis added); *see also id.* (considering section 3.3.1 “as a whole”).)  
5 Seagen disagrees with the Arbitrator’s interpretation of the “hereby assigns” clause, but  
6 Seagen cannot argue that the Arbitrator ignored it. As DSC argues, the Arbitrator found  
7 that Seagen did not own DSC’s alleged “Improvement IP” and, consequently, there was  
8 no property for DSC to “hereby assign” in the first place. (*See* Def. Mem. at 12.)

9 Accordingly, the Arbitrator neither disregarded the controlling law nor ignored the  
10 “hereby assigns” clause in the collaboration agreement. The Arbitrator’s conclusions  
11 concerning the statute of limitations are therefore neither completely irrational nor a  
12 manifest disregard for the law. The court AFFIRMS the Award on this ground.

### 13 **C. Attorneys’ Fees**

14 Seagen’s final argument concerns the Arbitrator’s award of attorneys’ fees to  
15 DSC. Seagen makes three arguments, each of which fails.

16 First, Seagen argues that “[t]he magnitude of th[e] fee award is ‘completely  
17 irrational’ in its own right.” (Pet. Mem. at 22.) Seagen’s conclusory statement is not  
18 enough. Seagen cites no case law establishing a bright-line rule concerning the  
19 “magnitude” of fee awards, makes no further attempt to explain its position, and ignores  
20 the circumstances surrounding this litigation—“a highly complex intellectual property  
21 dispute between sophisticated corporate entities with billions of dollars at stake.” (Award

22 //

1 at 58). The court therefore declines to scrap the Arbitrator’s fee award based solely on its  
2 “magnitude.” (Pet. Mem. at 22.)

3         Second, Seagen argues that the Arbitrator “gave no weight to the fact that Seagen,  
4 using the same billing rates, litigated the same case for \$16 million.” (Pet. Mem. at 22.)  
5 Seagen mischaracterizes the Award. The Arbitrator found this exact argument “not  
6 availing” and “conclude[d] that the disparity in attorneys’ fees incurred by the Parties  
7 [was] not surprising” because DSC and Seagen were not “similarly situated . . . in the  
8 critical sense that DSC was required to gather evidence (dating back decades, across  
9 continents, in various forms and languages) and craft complex legal arguments (from  
10 various disciplines) in an effort to defend itself across the full spectrum of Seagen’s very  
11 broad affirmative claims.” (Award at 61-62.) Seagen argues in conclusory fashion that  
12 the Arbitrator “had no rational basis to find that DSC justifiably spent nearly three times  
13 more to litigate the same case,” but Seagen fails to address the Arbitrator’s well-reasoned  
14 explanation in response to this very point. (Pet. Mem. at 22.)

15         Third, Seagen argues that the Arbitrator erred by finding that DSC’s 113-page  
16 categorical chart “presumptively validate[d]” its fee request and improperly shifted the  
17 burden to Seagen. (*Id.*) Seagen cherry-picks this language from the Award while  
18 ignoring key aspects of the Arbitrator’s analysis. In whole, the sentence Seagen quotes  
19 reads as follows: “The Arbitrator finds that by providing the information organized  
20 within [the categorical chart], DSC has demonstrably satisfied the threshold requirement  
21 under Washington State law of facilitating the calculation of a lodestar base that  
22 presumptively validates the attorneys’ fees it has requested.” (Award at 55.) The

1 Arbitrator “thoroughly reviewed” DSC’s submission and was “clearly convinced that  
2 DSC ha[d] carried its burden of proving that its requested attorneys’ fees [were]  
3 ‘reasonable.’” (*Id.* at 54-55.) The Arbitrator then correctly recognized that Seagen, as  
4 the party proposing a deviation from the lodestar base, had the burden of justifying any  
5 such deviation. (*See id.* at 54 (citing *Bowers*, 675 P.2d at 597-600)); *see also* 224  
6 *Westlake, LLC v. Engstrom Props., LLC*, 281 P.3d 693, 712 (Wash Ct. App. 2012) (“The  
7 party proposing the deviation from the lodestar bears the burden of justifying it.”).  
8 Seagen’s argument that the Arbitrator “presumptively” accepted DSC’s fee request again  
9 mischaracterizes the Arbitrator’s Award, and this argument is not well taken. The court  
10 concludes that the Arbitrator’s grant of reasonable attorneys’ fees was neither completely  
11 irrational nor a manifest disregard for the law.

12 The court therefore AFFIRMS the Arbitrator’s award of \$43,710,217.20 in  
13 attorneys’ fees and \$1,856,915.10 and ¥169,076 in costs.

#### 14 V. POST-AWARD PREJUDGMENT INTEREST

15 Having affirmed the Arbitrator’s Award, the court considers DSC’s request for  
16 post-award prejudgment interest on the total amount of \$45,567,132.30 and ¥169,076.  
17 (*See* Resp. Mem. at 24-25.) DSC’s request is well taken.

18 “Courts presume that post-award, prejudgment interest is ‘appropriate’ absent a  
19 persuasive showing to the contrary,” and the decision to award such interest “falls with  
20 the district court’s discretion.” *Purus Plastics GmbH v. Eco-Terr Distrib., Inc.*, No.  
21 C18-0227JLR, 2018 WL 3064817, at \*10 (W.D. Wash. June 21, 2018) (first citing *Al*  
22 *Maya Trading Establishment v. Glob. Exp. Mktg. Co.*, No. 16-CV-2140 (RA), 2017 WL

1 1050123, at \*5 (S.D.N.Y. Mar. 17, 2017); and then citing *Ministry of Def. & Support for*  
2 *the Armed Forces of the Islamic Republic of Iran v. Cubic Def. Sys., Inc.*, 665 F.3d 1091,  
3 1100 (9th Cir. 2011)). Prejudgment interest should not, however, be awarded as a  
4 “penalty,” *Dishman v. UNUM Life Ins. Co. of Am.*, 269 F.3d 974, 988 (9th Cir. 2001), or  
5 if it would constitute a “windfall recovery,” *Knapp v. Ernst & Whinney*, 90 F.3d 1431,  
6 1442 (9th Cir. 1996). Rather, the decision to award prejudgment interest is a “question of  
7 fairness . . . to be answered by balancing the equities.” *Wessel v. Buhler*, 437 F.2d 279,  
8 284 (9th Cir. 1971).

9 Here, equity favors granting post-award prejudgment interest. The Arbitrator  
10 concluded that DSC was entitled to its reasonable attorneys’ fees and costs; post-award  
11 prejudgment interest is part of DSC’s “complete compensation.” *Osterneck v. Ernst &*  
12 *Whinney*, 489 U.S. 169, 175 (1989). This award is neither a windfall nor a punishment.  
13 The Agreement provided that the prevailing party should recover its reasonable costs and  
14 attorneys’ fees (Collaboration Agreement at 33), and prejudgment interest appropriately  
15 compensates DSC for the time value of money, *see Hunter v. Allis-Chalmers Corp.*, 797  
16 F.2d 1417, 1426 (7th Cir. 1986) (Posner, J.) (“[F]ull compensation requires recognition  
17 of the time value of money.”), *abrogated on other grounds as recognized in Malhotra v.*  
18 *Cotter & Co.*, 885 F.2d 1305, 1312 (7th Cir. 1989). The court therefore GRANTS DSC’s  
19 request for post-award prejudgment interest and applies the rate set forth in 28 U.S.C.  
20 § 1961(a) to the \$45,567,132.30 and ¥169,076 award from November 14, 2023, to the  
21 date of judgment.

22 //

## VI. POSTJUDGMENT INTEREST

1  
2 The court next considers DSC's request for postjudgment interest. (Resp. Mem. at  
3 25.) Seagen does not challenge DSC's request (*see generally* Pet. Reply), and the Ninth  
4 Circuit has held that an award of postjudgment interest "is mandatory, not discretionary,"  
5 *see Cubic*, 665 F.3d at 1102. The court therefore GRANTS DSC's request for  
6 postjudgment interest. Postjudgment interest shall be calculated from the date of the  
7 entry of judgment through the date of payment at the rate from 28 U.S.C. § 1961(a).

## VII. COSTS AND FEES FOR DISTRICT COURT PROCEEDINGS

8  
9 Finally, the court considers DSC's request for costs and fees incurred during these  
10 proceedings. DSC argues that Seagen acted in bad faith by making "cynical attacks on  
11 the Award" that went "beyond legitimate advocacy." (Resp. Mem. at 26.) Seagen  
12 counters that it "had every reason to challenge the Award" and properly "acknowledged  
13 the substantial deference owed to arbitration awards, but showed that the Award here is  
14 'completely irrational,' disregards clear contract terms 'to dispense [its] own brand of  
15 industrial justice,' and exhibits a 'manifest disregard of the law.'" (Pet. Reply at 14  
16 (quoting *Aspic Eng'g & Constr. Co.*, 913 F.3d at 1166-67).) The court concludes that  
17 Seagen's conduct did not rise to the level of sanctionable bad faith.

18 "A prevailing litigant ordinarily may not collect attorneys' fees." *Dogherra v.*  
19 *Safeway Stores, Inc.*, 679 F.2d 1293, 1298 (9th Cir. 1982). There is an exception,  
20 however, if "the losing party has acted in bad faith, vexatiously, wantonly or for  
21 oppressive reasons." *Cubic*, 665 F.3d at 1104. Such awards are punitive and can be  
22 imposed "only in exceptional cases and for dominating reasons of justice." *Dogherra*,

1 679 F.2d at 1298 (quoting *United States v. Standard Oil Co.*, 603 F.2d 100, 103 (9th Cir.  
2 1979)). Examples of bad faith include the use of “frivolous dilatory tactics” and “an  
3 unjustified refusal to abide by an arbitrator’s award.” *Int’l Union of Petroleum & Indus.*  
4 *Workers v. W. Indus. Maint., Inc.*, 707 F.2d 425, 428 (9th Cir. 1983).

5 Seagen walks the line between overzealous advocacy and sanctionable conduct,  
6 but the court concludes that its actions were not so egregious as to constitute bad faith.  
7 There is no indication that Seagen filed its petition to cause undue delay or that it has  
8 refused to abide by the Arbitrator’s Award. Although Seagen makes liberal use of  
9 hyperbole and frequently mischaracterizes the Arbitrator’s reasoning in the Award, the  
10 court does not find that Seagen purposefully intended to deceive the court or lie about the  
11 record. Seagen’s briefing is disappointing and at times evinces a lack of candor, but  
12 “dominating reasons of justice” do not weigh in favor of sanctions here. DSC has  
13 vindicated its rights and is entitled to well over \$45,000,000 in fees and costs. The court  
14 will leave it at that.


#### 15 **VIII. CONCLUSION**

16 For the foregoing reasons, the court DENIES Seagen’s petition to vacate the  
17 Award (Dkt. # 78) and GRANTS DSC’s gross-motion to confirm the Award (Dkt.  
18 # 112). The court AFFIRMS the Arbitrator’s Award and AWARDS DSC prejudgment  
19 and postjudgment interest pursuant to 28 U.S.C. § 1961(a). The court DENIES DSC’s  
20 request for additional costs and fees incurred during the district court proceedings.

21 Pursuant to the court’s January 16, 2024 order, the parties are ORDERED to meet  
22 and confer and file redacted versions of Exhibits 1 and 6 to the December 13, 2023

1 declaration of Matthew Chivvis on the docket. (See 1/16/24 Order at 2.) The parties  
2 must do so by no later than April 12, 2024.

3 Dated this 1st day of April, 2024.

4 

5 JAMES L. ROBERT  
6 United States District Judge  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22